



Date: 20<sup>th</sup> July, 2016

To,

The Bombay Stock Exchange Limited

The National Stock Exchange of India Limited

Floor 25, P.J. Towers  
Dalal Street  
Mumbai 400 001

Exchange Plaza, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai 400 051

Kind Attn.: Mr. Gopal K Iyer.

Kind Attn.: Mr. Hari K.

Dear Sir,

**Sub.: Quarterly Statement on Investor Complaints**

We furnish hereunder the statement Pursuant to Regulation 13(3) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, in respect of the quarter ended 30<sup>th</sup> June, 2016

Sr. No.	Details	No. of Complaints
1.	No. of Investors Complaints pending at the beginning of the Quarter	NIL
2.	No. of Complaints received during the Quarter	NIL
3.	No. of Complaints disposed of during the Quarter	NIL
4.	No. of Complaints remaining unsolved at the end of the Quarter	NIL

This is for your information and record.

Thanking You

Yours Sincerely,  
For PLETHICO PHARMACEUTICALS LIMITED

  
SHASHIKANT PATEL  
MANAGING DIRECTOR  
(DIN:00199120)



**PLETHICO PHARMACEUTICALS LIMITED**

Regd. Office : A.B. Road, Manglia - 453 771, Dist. - Indore (M.P.) Tel.: +91-731-2806275, +91-731-2806271  
Website : www.plethico.com E-mail : info@plethico.com CIN No. L24232MP1991PLC006801